NasdaqGM:HROWPharmaceuticals
Is It Too Late To Consider Harrow (HROW) After Its Recent Share Price Surge
Wondering whether Harrow at US$40.50 still offers value, or if most of the opportunity is already priced in? This article is built to help you frame that question clearly.
The stock has returned 14.7% over the past 30 days, sits on a 67.9% return over 1 year, but is still down 18.9% year to date. This raises fair questions about both upside potential and risk.
Recent coverage has focused on Harrow's position in the pharmaceuticals space and how investors are reacting to its latest...